BlogHotel.orgAccueil | Créer un blog | Imprimer la page Imprimer | Blog hasard Au hasard | Chercher des blogs Rechercher | Entrer dans le chat du blog Chat | | Jeux Jeux | Adminitration et édition du Blog Manager

freemexy Accueil | Profil | Archives | Amis
freemexy

Spanish youngster returns adverse finding for terbutaline powder8/11/2019
Xuban Errazkin, a young Basque rider, is facing an anti-doping ordeal after two separate adverse analytical findings for terbutaline. wisepoqder Terbutaline powder

The 21-year-old, who rides for the Vito-Feirense-BlackJack team, recently won the best young rider classification at the Volta a Portugal, but two months previously returned two Adverse Analytical Findings (AAF) for the asthma drug at the Gran Premio Abimota, as revealed by Portuguese newspaper, Record.

Terbutaline is on the World Anti-Doping Agency's banned list but is permitted with the possession of a Therapeutic Use Exemption (TUE). An AAF for the substance does not dictate a provisional suspension but, similarly to Chris Froome's recent salbutamol case, he will now have to answer to the authorities.

Terbutaline is the substance for which Simon Yates tested positive in 2016. The British rider claimed it was due to an administration error from his team in not registering the TUE, and he was banned for four months for a 'non-intentional' rule violation.

Errazkin maintains he is innocent and his case has now been handed to the Spanish Anti-Doping Agency, who will decide whether or not a sanction is applicable.

"Both myself and my team have decided to send all the necessary documentation, including from before I was personally notified of the positive," Errazkin told the Spanish website, SprintFinal. "I have been treating my asthma for several years and have never had any problems."

A couple of days before the news of the AAFs broke, Errazkin was left out of Spain's squad for the upcoming Tour de l'Avenir, a decision which surprised many given his form in the U23 ranks and his role in amassing the points needed to qualify for the event.

However, the national coach, Pascual Momparler, insisted Errazkin's absence was not linked to the doping case. "

The reason he wasn't selected was because I spoke to him a while ago to tell him to prepare for the race like the rest of the riders in the pre-selection - I wanted them to be fresh and and be able to perform at 100 per cent in France and then go on to the World Championships," Momparler told Ciclo21.

0 Commentaires | poster un commentaire | Lien Permanent

Tamoxifen powder Prevention Does not Benefit most Women8/11/2019
We found that for women at the lower end of the high-risk range for developing breast cancer, there is a very small likelihood that taking tamoxifen will reduce mortality," said Joy Melnikow, professor of family and community medicine at UC Davis School of Medicine and Medical Center. "This would support revising the current recommended risk threshold for physicians to counsel women about tamoxifen."wisepoqder Tamoxifen

Tamoxifen was approved by the U.S. Food and Drug Administration in 1998 for breast cancer prevention in women who have at least a 1.67-percent chance of developing the disease over the next five years. Such women are considered at high risk for breast cancer. Groups such as the U.S. Preventive Services Task Force and the Canadian Task Force on Preventive Health Care recommend that physicians counsel women above this threshold about the benefits and risks of tamoxifen as a means of preventing the disease.
Tamoxifen is a selective estrogen receptor-modulating drug used to treat estrogen receptor-positive breast cancers. In addition, it has been shown to reduce the incidence of invasive breast cancer among high-risk women by up to 49 percent.
However, tamoxifen is associated with significant adverse effects, including cataracts requiring surgery, deep vein thromboses, endometrial cancer and stroke. Women taking tamoxifen, if they do develop breast cancer, are also more likely to develop an estrogen receptor-negative tumor, which has a worse prognosis.
In the new study, Melnikow and her colleagues calculate that tamoxifen can be expected to extend life expectancy only when a woman's five-year risk of developing breast cancer reaches 3 percent or more. This is especially true for women who have not had a hysterectomy, and therefore face the risk of endometrial cancer related to tamoxifen use.
To arrive at their findings, Melnikow and her colleagues used a complex mathematical model based on a hypothetical group of 50-year-old women.

0 Commentaires | poster un commentaire | Lien Permanent

Page 199 of 834
Précédent | Suivant